4-ethyl-1-methyl-1H-indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-ethyl-1-methyl-1H-indole
• 英文别名: 4-Ethyl-1-methylindole
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: GWOJZBMFXGEYHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  4-甲氧基-1-甲基吲哚 、 三乙基铝 在 bis(1,5-cyclooctadiene)nickel (0) 、 1,2-双(二环己基磷基)-乙烷 作用下， 以 异丙醚 、 甲苯 为溶剂， 反应 72.08h， 以98%的产率得到4-ethyl-1-methyl-1H-indole
  参考文献：
  名称：

  路易斯酸通过C-O键裂解烷基化辅助芳基甲基醚的镍催化交叉偶联：防止不希望的β-氢化物消除

  摘要：

  在存在三烷基铝试剂的情况下，可以通过C-O键裂解烷基化将多种芳基甲基醚首次转化为有价值的产物，而不会限制β-氢化物的消除。这种新的镍催化脱烷氧基化烷基化方法可实现强大的正交合成策略，用于转化多种天然存在且易于获得的苯甲醚衍生物。首先利用芳族甲氧基的导向和/或活化性能，然后在随后的偶联过程中将其用烷基链取代。

  DOI：

  10.1002/anie.201510497

文献信息

• INHIBITORS OF SYK AND JAK PROTEIN KINASES
  申请人：Jia Zhaozhong

  公开号：US20120101275A1

  公开（公告）日：2012-04-26

  The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及公式I-V和其互变异构体或药学上可接受的盐、酯和前药的化合物，其为syk激酶的抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的制药组合物，抑制syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由syk激酶活性介导的多种情况的方法，如非霍奇金淋巴瘤和不良血栓形成。
• Spiroketone Acetyl-CoA Carboxylase Inhibitors
  申请人：Corbett Jeffrey Wayne

  公开号：US20090270435A1

  公开（公告）日：2009-10-29

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

  本发明提供了式（1）的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8和R9如本文所述；其药物组成物；以及将其用于治疗患有超重症的哺乳动物。
• Diaminopyrimidinecarboxamide Derivative
  申请人：Nagashima Shinya

  公开号：US20090281072A1

  公开（公告）日：2009-11-12

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗呼吸系统疾病，特别是哮喘、慢性阻塞性肺疾病等与STAT 6有关的化合物。该化合物为嘧啶衍生物或其盐，其在2位具有可被取代的芳基氨基或芳基乙基氨基基团，4位具有氨基取代的苯甲基基团或类似基团，5位具有可被取代的氨基甲酰基团。
• DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE
  申请人：Nagashima Shinya

  公开号：US20110294749A1

  公开（公告）日：2011-12-01

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗涉及STAT 6的呼吸系统疾病，特别是哮喘、慢性阻塞性肺疾病等的化合物。该化合物为嘧啶衍生物或其盐，其在2位具有可以被指定取代基取代的芳基氨基或芳基乙基氨基基团，在4位具有可以被苄基或类似物取代的氨基基团，并在5位具有可以被取代的氨基甲酰基团。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150353495A1

  公开（公告）日：2015-12-10

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及式I化合物及其药学上可接受的盐、酯和前药，它们是JAK激酶抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由JAK激酶活性介导的多种疾病，如不良血栓形成和非霍奇金淋巴瘤的方法。